Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3468-3477

  Zhang, Xuehong ^a   Smith Warner, Stephanie A ^b   Collins, Laura C ^c   Rosner, Bernard ^a,b   Willett, Walter C ^a,b   Hankinson, Susan E ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; DRUG USE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

ACETAMINOPHEN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; QUESTIONNAIRES;

EID: 84867050688     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.2006     Document Type: Article

References (59)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
2. World Cancer Research Fund, American Institute for Cancer Research Expert Panel: Food, Nutrition, and the Prevention of Cancer: A Global Perspective. Washington, DC, American Institute for Cancer Research, 2007
3. Dube C, Rostom A, Lewin G, et al: The use of aspirin for primary prevention of colorectal cancer: A systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 146:365-375, 2007 (Pubitemid 351650597)
4. Flossmann E, Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369:1603-1613, 2007 (Pubitemid 46710123)
5. Howe LR: Inflammation and breast cancer: Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9:210, 2007
6. Howe LR, Subbaramaiah K, Brown AM, et al: Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8:97-114, 2001 (Pubitemid 32641352)
7. Thun MJ, Blackard B: Pharmacologic effects of NSAIDs and implications for the risks and benefits of long-term prophylactic use of aspirin to prevent cancer. Recent Results Cancer Res 181:215-221, 2009
8. Wang D, Dubois RN: Prostaglandins and cancer. Gut 55:115-122, 2006 (Pubitemid 41820645)
9. Ristimaki A, Sivula A, Lundin J, et al: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62:632-635, 2002 (Pubitemid 34126931)
10. Zhao Y, Agarwal VR, Mendelson CR, et al: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742, 1996 (Pubitemid 26423150)
11. Hankinson SE, Colditz GA, Willett WC: Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6:213-218, 2004
12. Takkouche B, Regueira-Méndez C, Etminan M: Breast cancer and use of nonsteroidal antiinflammatory drugs: A meta-analysis. J Natl Cancer Inst 100:1439-1447, 2008
13. Bosetti C, Gallus S, La Vecchia C: Aspirin and cancer risk: An updated quantitative review to 2005. Cancer Causes Control 17:871-888, 2006 (Pubitemid 44081706)
14. González-Pérez A, García Rodríguez LA, López-Ridaura R: Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis. BMC Cancer 3:28, 2003
15. Luo T, Yan HM, He P, et al: Aspirin use and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 131:581-587, 2012
16. Eliassen AH, Chen WY, Spiegelman D, et al: Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses'Health Study II. Arch Intern Med 169:115-121, 2009; discussion 121
17. Gill JK, Maskarinec G, Wilkens LR, et al: Nonsteroidal antiinflammatory drugs and breast cancer risk: The multiethnic cohort. Am J Epidemiol 166:1150-1158, 2007 (Pubitemid 350022753)
18. Jacobs EJ, Thun MJ, Connell CJ, et al: Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort.Cancer Epidemiol Biomarkers Prev 14:261-264, 2005 (Pubitemid 40165311)
19. Marshall SF, Bernstein L, Anton-Culver H, et al: Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805-812, 2005 (Pubitemid 40909123)
20. Zhang SM, Cook NR, Manson JE, et al: Low-dose aspirin and breast cancer risk: Results by tumour characteristics from a randomised trial. Br J Cancer 98:989-991, 2008 (Pubitemid 351341601)
21. Gierach GL, Lacey JV Jr, Schatzkin A, et al: Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 10:R38, 2008
22. Terry MB, Gammon MD, Zhang FF, et al: Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433-2440, 2004 (Pubitemid 38669186)
23. Harris RE, Chlebowski RT, Jackson RD, et al: Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the Women's Health Initiative. Cancer Res 63:6096-6101, 2003 (Pubitemid 37187516)
24. Rahme E, Ghosn J, Dasgupta K, et al: Association between frequent use of nonsteroidal antiinflammatory drugs and breast cancer. BMC Cancer 5:159, 2005
25. Gallicchio L, Visvanathan K, Burke A, et al: Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211-215, 2007 (Pubitemid 46753870)
26. Bardia A, Olson JE, Vachon CM, et al: Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: Results from a prospective cohort study. Breast Cancer Res Treat 126:149-155, 2011
27. Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363:1938-1948, 2010
28. De Laurentiis M, Cianniello D, Caputo R, et al: Treatment of triple negative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev 36:S80-S86, 2010 (suppl 3)
29. Brasky TM, Bonner MR, Moysich KB, et al: Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: Differences by molecular subtype. Cancer Causes Control 22:965-975, 2011
30. Colditz GA, Manson JE, Hankinson SE: The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6:49-62, 1997
31. Egan KM, Stampfer MJ, Giovannucci E, et al: Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88:988-993, 1996 (Pubitemid 26239387)
32. Viswanathan AN, Feskanich D, Schernhammer ES, et al: Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res 68:2507-2513, 2008 (Pubitemid 351521827)
33. Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995
34. Chan AT, Giovannucci EL, Meyerhardt JA, et al: Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294:914-923, 2005 (Pubitemid 41215460)
35. Manson JE, Stampfer MJ, Colditz GA, et al: A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 266:521-527, 1991
36. Tamimi RM, Baer HJ, Marotti J, et al: Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67, 2008
37. Holmes MD, Chen WY, Schnitt SJ, et al: COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat 130:657-662, 2011
38. Dawood S, Hu R, Homes MD, et al: Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study. Breast Cancer Res Treat 126:185-192, 2011
39. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
40. SAS Institute: SAS/STAT software: The PHREG procedure: Preliminary documentation. Cary, NC, SAS Institute, 1991
41. Cook NR, Lee IM, Gaziano JM, et al: Low-dose aspirin in the primary prevention of cancer: The Women's Health Study - A randomized controlled trial. JAMA 294:47-55, 2005 (Pubitemid 41002838)
42. Ready A, Velicer CM, McTiernan A, et al: NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 109:533-543, 2008 (Pubitemid 351692052)
43. Friis S, Thomassen L, Sorensen HT, et al: Nonsteroidal anti-inflammatory drug use and breast cancer risk: A Danish cohort study. Eur J Cancer Prev 17:88-96, 2008 (Pubitemid 351301619)
44. Johnson TW, Anderson KE, Lazovich D, et al: Association of aspirin and nonsteroidal antiinflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 11:1586-1591, 2002 (Pubitemid 36020011)
45. Brasky TM, Bonner MR, Moysich KB, et al: Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 21:1503-1512, 2010
46. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
47. Holmes MD, Chen WY, Li L, et al: Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467-1472, 2010
48. Gasic GJ, Gasic TB, Stewart CC: Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 61:46-52, 1968
49. Gasic GJ, Gasic TB, Galanti N, et al: Platelet-tumor-cell interactions in mice: The role of platelets in the spread of malignant disease. Int J Cancer 11:704-718, 1973
50. Gay LJ, Felding-Habermann B: Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123-134, 2011
51. Gasic GJ, Gasic TB, Murphy S: Antimetastatic effect of aspirin. Lancet 2:932-933, 1972
52. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379:1591-1601, 2012
53. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142, 2007 (Pubitemid 47010839)
54. Glover JA, Hughes CM, Cantwell MM, et al: A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer. Br J Cancer 105:13-17, 2011
55. Cramer DW, Liberman RF, Hornstein MD, et al: Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil Steril 70:371-373, 1998 (Pubitemid 28361500)
56. Harris RE, Kasbari S, Farrar WB: Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6:71-73, 1999
57. Meier CR, Schmitz S, Jick H: Association between acetaminophen or nonsteroidal anti-inflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22:303-309, 2002 (Pubitemid 34205168)
58. García Rodríguez LA, González-Pérez A: Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 91:525-529, 2004
59. Bosco JL, Palmer JR, Boggs DA, et al: Regular aspirin use and breast cancer risk in US black women. Cancer Causes Control 22:1553-1561, 2011